On Monday, Shares of Comcast Corporation (NASDAQ:CMCSA), lost -1.70% to $61.11.
Comcast Corporation, stated results for the quarter ended June 30, 2015.
Brian L. Roberts, Chairman and Chief Executive Officer of Comcast Corporation, said, “Our second quarter results, counting 11.3% revenue growth and 8.0% operating cash flow growth, demonstrate the strength and momentum we are seeing across our businesses. In Cable, high-speed Internet and business services continued to perform extremely well, and, significantly, this was the best second quarter video customer results we’ve had in nine years. Our focus on accelerating the deployment of our transformative X1 platform, in addition to efforts to improve customer service, are clearly making a difference, with lower churn across all product categories. NBCUniversal had an exceptional quarter, led by the record-breaking box office performances of Jurassic World and Furious 7 and continued strong momentum in our theme parks. In addition, NBC won the 2014-2015 broadcast season for adults 18-49. Our teams are executing incredibly well across our strong and diversified portfolio, and I am excited for what we can deliver in the rest of 2015 and beyond.”
Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments.
Shares of Perrigo Company plc Ordinary Shares (NYSE:PRGO), inclined 3.80% to $193.59, during its last trading session.
Mylan N.V., declared that it will hold its extraordinary general meeting of shareholders in connection with its projected acquisition of Perrigo Company plc (NYSE: PRGO; TASE) at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 at 1 p.m. Central European Time (CET).
Among other agenda items at the extraordinary general meeting, Mylan shareholders will meet to vote on the approval, under article 2:107a of the Dutch Civil Code, of the acquisition of all or any portion of the ordinary shares of Perrigo outstanding as of the consummation of such acquisition and the issuance of Mylan ordinary shares to Perrigo shareholders as part of the consideration in such acquisition.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API).
Finally, Arrowhead Research Corp (NASDAQ:ARWR), ended its last trade with -2.17% loss, and closed at $6.31.
Arrowhead Research Corporation, declared that it dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT. ARC-AAT is Arrowhead’s RNAi-based drug candidate for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD) that was recently granted orphan drug designation by the United States Food and Drug Administration. The clinical trial is presently enrolling patients at a single center in Australia and the company intends to open additional sites for enrollment in Europe, pending regulatory permission to proceed. The company anticipates to complete enrollment of the Phase 1 study by the end of 2015.
“Dosing the first alpha-1 patient with ARC-AAT is a milestone for Arrowhead and for patients with AATD. The aim of treatment with ARC-AAT is to halt progression and possibly reverse the liver injury and fibrosis associated with AATD, which presently has no approved therapy short of liver transplant. This is becoming a larger clinical problem that we believe ARC-AAT holds great potential to address,” said Bruce D. Given, M.D., Arrowhead’s Chief Operating Officer. “We would also like to thank the Alpha-1 Foundation and The Alpha-1 Project, who have agreed to assist support the development of ARC-AAT through funding and assistance with patient recruitment.”
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
